Silence Therapeutics PLC (fra:XRP2) Share Price

Company Profile

Business description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Contact
12 Hammersmith Grove
LondonW6 7AP
GBR
T: +44 2034576900
E: [email protected]
https://www.silence-therapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
88

Recommended

Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.

Ananya Chag | 27 April 2026

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.

Malik Ahmed Khan, CFA | 24 April 2026

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.

Mark Taylor | 24 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,990.80	20.60	0.23%
CAC 40	8,141.92	15.90	-0.19%
DAX 40	24,083.53	45.45	-0.19%
Dow JONES (US)	49,167.79	62.92	-0.13%
FTSE 100	10,321.09	57.99	-0.56%
HKSE	25,925.65	52.42	-0.20%
NASDAQ	24,887.10	50.50	0.20%
Nikkei 225	60,537.36	821.18	1.38%
NZX 50 Index	12,853.51	21.43	-0.17%
S&P 500	7,173.91	8.83	0.12%
S&P/ASX 200	8,766.40	17.20	0.20%
SSE Composite Index	4,086.34	6.44	0.16%